The company has not filed an annual or quarterly report since its Q1 FY2018 10-Q, filed May 15, 2018. Its latest SEC filing is a 15-12B from Jul 2, 2018.
10-Q for Q1 FY2018, filed May 15, 2018
The sections below describe the company as of the latest annual report.
Develops experimental cancer drugs that activate patients’ immune systems, including pegilodecakin and checkpoint inhibitors, for people with cancer.
10-K, filed Mar 30, 2018We are a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune…View ↗
Our lead product candidate, AM0010 (pegilodecakin), stimulates the survival, expansion and tumor killing (cytotoxic) capacity of a…View ↗
In addition to AM0010, our immuno-oncology pipeline includes a number of validated product candidates. AM0001 is our anti-PD-1 checkpoint…View ↗
10-Q for Q1 FY2018, filed May 15, 2018
−$21.7MView ↗
8-K, filed Jun 22, 2018
On June 22, 2018, ARMO (i) notified The Nasdaq Stock Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq (x)…View ↗
8-K, filed May 10, 2018
INDIANAPOLIS, IN and REDWOOD CITY, CA – Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a…View ↗
Competes with Bristol-Myers Squibb, Merck, Roche, AstraZeneca, and Merck KGaA
10-K, filed Mar 30, 2018To our knowledge there are no other IL-10 cytokine programs in clinical development for oncology. Our initial targeted indications for…View ↗
Loading...
